P16 and P53 Play Distinct Roles in Different Subtypes of Breast Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Shan, Ming ^a   Zhang, Xianyu ^a   Liu, Xiaolong ^a   Qin, Yu ^a   Liu, Tong ^a   Liu, Yang ^a   Wang, Ji ^a   Zhong, Zhenbin ^a   Zhang, Youxue ^a   Geng, Jingshu ^a   Pang, Da ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LUMINAL A GENE; LUMINAL B GENE; ONCOGENE; ONCOGENE NEU; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADOLESCENT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; RISK FACTORS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84885416415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076408     Document Type: Article

References (41)

1. Montanari M, Boninsegna A, Faraglia B, Coco C, Giordano A, et al. (2005) Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors. J Cell Physiol 202: 215-222.
2. Sherr CJ, McCormick F, (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
3. Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD, (2006) p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 66: 10325-10331.
4. Stewart CL, Soria AM, Hamel PA, (2001) Integration of the pRB and p53 cell cycle control pathways. J Neurooncol 51: 183-204.
5. Pavletich NP, (1999) Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821-828.
6. Oliveira AM, Ross JS, Fletcher JA, (2005) Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124Suppl: S16-28.
7. Radpour R, Barekati Z, Haghighi MM, Kohler C, Asadollahi R, et al. (2010) Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 23: 763-772.
8. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD, (2001) Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409: 633-637.
9. Witcher M, Emerson BM, (2009) Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 34: 271-284.
10. Levine AJ, Finlay CA, Hinds PW (2004) P53 is a tumor suppressor gene. Cell 116: S67-69, 1 p following S69.
11. Hainaut P, Hollstein M, (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137.
12. Perou CM, Sorlie T, Eisen MB, de Rijn M v, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
15. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, et al. (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27: 1168-1176.
16. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
17. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, et al. (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16: 439-443.
18. Bartley AN, Ross DW, (2002) Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med 126: 456-458.
19. Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, et al. (2000) INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 6: 2777-2787.
20. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
21. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T, (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70.
22. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, et al. (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9: R30.
23. Zhang D, Shimizu T, Araki N, Hirota T, Yoshie M, et al. (2008) Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene 27: 4305-4314.
24. Turner NC, Reis-Filho JS, (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846-5853.
25. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, et al. (2007) Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12: 479-491.
26. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, et al. (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212.
27. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ, (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.
28. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
29. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, et al. (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27: 1050-1055.
30. Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, et al. (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109.
31. Borresen-Dale AL, (2003) TP53 and breast cancer. Hum Mutat 21: 292-300.
32. Herschkowitz JI, He X, Fan C, Perou CM, (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10: R75.
33. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P, (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18: 2-11.
34. Geradts J, Ingram CD, (2000) Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol 13: 945-953.
35. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM, (1998) Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 79: 71-75.
36. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, et al. (2004) Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5: 263-273.
37. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG, (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 96: 12754-12759.
38. Silva J, Silva JM, Dominguez G, Garcia JM, Cantos B, et al. (2003) Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol 199: 289-297.
39. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, et al. (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38: 197-204.
40. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, et al. (2012) Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell 148: 244-258.
41. Derenzini M, Brighenti E, Donati G, Vici M, Ceccarelli C, et al. (2009) The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein. J Pathol 219: 373-382.